Shattuck Labs has completed its restructuring plan, which involved prioritizing the development of its DR3 program and aligning the company's cost and workforce structure with its current goals. This strategic move follows the discontinuation of the SL-172154 program.
The company has substantially completed the reduction in force associated with the termination of the SL-172154 program. This action aims to streamline operations and focus resources on the most promising pipeline candidates.
Shattuck Labs confirmed that its cash and cash equivalents and investments are sufficient to fund planned operations into 2027. This financial runway extends beyond the expected results from its Phase 1 clinical trial of SL-325, providing stability for its new strategic direction.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.